New book, 'The Creative Destruction of Medicine,' outlines digital health care revolution

January 18, 2012

SAN DIEGO (Jan. 18 , 2012) - The inventions of cell phones, personal computers, and the Internet ushered in the digital revolution and altered our existence in ways that were unimaginable just a few decades ago. But the most precious part of our existence--our health--has so far been largely unaffected and insulated from these innovations.

Now, we are on the verge of a medical revolution. In "The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care" (Basic Books, available in hardcover Feb. 1, 2012), Eric Topol, M.D. introduces the digital future of medicine and explores how digitization will fundamentally change the medical field for both professionals and patients.

According to Dr. Topol, the chief academic officer of Scripps Health, we're at perhaps the greatest convergence in our history: the rapidly maturing digital, nonmedical world of mobile devices, cloud computing, and social networking is finally coalescing with the emerging digital medical world of genomics, biosensors, and advancing imaging.

Furthermore, the digital medical fields are already supplying a wealth of innovation. Pocket-sized ultrasound devices, at-home sleep monitors, and air strip technology that can measure everything from calorie intake to oxygen level are currently available. Nanosensors that can anticipate heart attacks and detect the first instance of cancer and breath sensors that can track lung cancer and asthma are in development. Similarly, the sequencing of the human genome has opened a new door in medical discovery; as sequencing becomes both faster and more affordable, Dr. Topol notes, it will become a routine procedure for every individual and the backbone of a patient's medical history, determining both testing and treatment procedures.

Drawing on his own experience as a practicing cardiologist, as well as other case studies, Dr. Topol opens "The Creative Destruction of Medicine" by explaining how medicine works today: Treatments are based on the population, not the individual. Digital medicine - including wireless sensors, genomics, imaging, and electronic health records and health information technology systems - has the power to radically change that. "This is a new era of medicine, in which each individual can be near fully defined at the individual level, instead of how we practice medicine at a population level, with mass screening policies for such conditions as breast or prostate cancer and use of the same medication and dosage for a diagnosis rather than for a patient," he writes.

Yet Dr. Topol acknowledges that there will be challenges along the way: physicians may be tempted to treat the scan or the DNA data, not the patient; the privacy and security of our data may be compromised; and ethical dilemmas and controversies may arise when, for example, a couple can screen for thousands of rare mutations they may carry before conceiving a baby. Yet Dr. Topol believes that the advantages of individualized medicine far outweigh any challenges we'll face. By leveraging the science of individuality, doctors will be able to get the relevant digital readout from a person to fashion a therapy, instead of using a mass-population-directed strategy. "We now have the tools to do this on a broad basis throughout medicine and for the first time promote a level of prescription precision we have never seen before," he writes.

"Our system has to change," Dr. Topol concludes. "It has to reboot. We need creative destruction of the old rules." In "The Creative Destruction of Medicine," he shows the way to do just that.

Eric Topol, M.D. is the chief academic officer of Scripps Health, director of the Scripps Translational Science Institute and co-founder and vice-chairman of the West Wireless Health Institute in La Jolla, California. He is a practicing cardiologist at the Scripps Clinic and a professor of genomics at The Scripps Research Institute. One of the top ten most cited researchers in medicine, elected to the Institute of Medicine of the National Academy of sciences, named as one of the twelve Rock Stars of Science in GQ, Dr. Topol led many of the trials that have shaped contemporary treatment for heart disease. Twitter: @EricTopol


The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care
By Eric Topol, M.D.
Published by Basic Books
Publication date: February 1, 2012
ISBN: 978-0-465-02550-3 • $27.99 / $31.00 (CAN) • Hardcover • 320 pages
Ebook ISBN: 978-0-465-02934-1


Founded in 1924 by philanthropist Ellen Browning Scripps, Scripps Health is a $2.45 billion nonprofit integrated health system based in San Diego, Calif. Scripps treats a half-million patients annually through the dedication of 2,600 affiliated physicians and 13,000 employees among its five acute-care hospital campuses, home health care services, and an ambulatory care network of physician offices and 23 outpatient centers and clinics. Recognized as a leader in the prevention, diagnosis, and treatment of disease, Scripps is also at the forefront of clinical research, genomic medicine, wireless health care and graduate medical education. With three highly respected graduate medical education programs, Scripps is a longstanding member of the Association of American Medical Colleges. More information can be found at

Media Contact:
Steve Carpowich, Scripps Health

Scripps Health

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to